Neurological complications of infliximab.

Authors:
  • DZDouglas W Zochodne
    Douglas W Zochodne
  • LMLiam O Martin
    Liam O Martin
  • CVChristopher Voll
    Christopher Voll

  • 1 March 2006
    • journal article
    • case report
Abstract
The use of anti-tumor necrosis factor-a (TNF-a) therapies has led to improved outcomes in the treatment of rheumatoid arthritis (RA). However, the use of these new therapeutic agents requires careful monitoring for adverse effects. We describe 3 patients who developed neurological disease closely associated with the use of infliximab, a monoclonal antibody that binds to and inactivates TNF-a. All had evidence of polyneuropathy, demyelinating in one and axonal in 2. One patient had a central nervous system syndrome. Physicians should be aware of these potential adverse effects when treating patients with infliximab.